All In Biotech

Drug Trial Radar · NCT06362759

A Study to Evaluate TOUR006 in Patients With Chronic Kidney Disease and Elevated Hs-CRP

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Quarterly and Monthly TOUR006 in Participants With Chronic Kidney Disease and Elevated High-Sensitivity C-Reactive Protein

Last checked: Nov 19, 2026Latest source record: Aug 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 143 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

143

Actual

Start

May 15, 2024

Primary completion

Mar 6, 2025

Study completion Dec 4, 2025

Sponsor

Sponsor type
Industry
First posted
Apr 12, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the safety, tolerability, pharmacokinetics, and CRP-lowering effect of quarterly and monthly subcutaneous administration of TOUR006 (also known as pacibekitug) in participants with chronic kidney disease and elevated hs-CRP.

Conditions

  • Chronic Kidney Diseases
  • Chronic Kidney Insufficiency
  • Chronic Renal Diseases
  • Chronic Renal Insufficiency
  • Kidney Insufficiency, Chronic
  • C-Reactive Protein
  • High Sensitivity C-Reactive Protein
  • Hs-CRP
  • hsCRP

Interventions

  • TOUR006 - 50 MGDrug

    TOUR006 50 MG

  • TOUR006 - 25 MGDrug

    TOUR006 25 MG

  • TOUR006 - 15 MGDrug

    TOUR006 15 MG

  • PlaceboOther

    Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time-Averaged Percent Change From Baseline in High-Sensitivity C-Reactive Protein (Hs-CRP) Through Day 90Time frame: Baseline through 90 days. Baseline is defined as the average of the last two available visits prior to study treatment administration.

Locations

38 sites in 1 country. Site status is shown where the registry gives one.

  • Site - 0101

    Birmingham, Alabama

  • Site - 0135

    Huntsville, Alabama

  • Site - 0145

    Huntsville, Alabama

  • Site - 0104

    Phoenix, Arizona

  • Site - 0125

    San Dimas, California

  • Site - 0112

    Valencia, California

  • Site - 0128

    Valencia, California

  • Site - 0136

    Stamford, Connecticut

  • Site - 0113

    Greenacres City, Florida

  • Site - 0149

    Pembroke Pines, Florida

  • Site - 0144

    Plantation, Florida

  • Site - 0119

    Port Orange, Florida

  • Site - 0151

    Tampa, Florida

  • Site - 0122

    Savannah, Georgia

  • Site - 0106

    Chicago, Illinois

  • Site - 0115

    Morton, Illinois

  • Site - 0114

    Council Bluffs, Iowa

  • Site - 0129

    Metairie, Louisiana

  • Site - 0123

    Las Vegas, Nevada

  • Site - 0130

    Middletown, New York

  • Site - 0110

    Charlotte, North Carolina

  • Site - 0117

    Fargo, North Dakota

  • Site - 0120

    Cincinnati, Ohio

  • Site - 0127

    Marion, Ohio

  • Site - 0132

    Bethlehem, Pennsylvania

  • Site - 0126

    Providence, Rhode Island

  • Site - 0102

    Fort Mill, South Carolina

  • Site - 0103

    Greenville, South Carolina

  • Site - 0108

    Knoxville, Tennessee

  • Site - 0148

    Greenville, Texas

  • Site - 0105

    Houston, Texas

  • Site - 0111

    Lampasas, Texas

  • Site - 0150

    McKinney, Texas

  • Site - 0107

    San Antonio, Texas

  • Site - 0141

    San Antonio, Texas

  • Site - 0109

    Manassas, Virginia

  • Site - 0147

    Morgantown, West Virginia

  • Site - 0134

    Kenosha, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.